Skip to main content
See every side of every news story
Published loading...Updated

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

Summary by Joplin Globe
RAHWAY, N.J.--(BUSINESS WIRE)--Sep 18, 2026-

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Joplin Globe broke the news on Friday, September 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal